Fluorodopa F 18

(Fluorodopa F 18®)

Fluorodopa F 18

Latest News

loading GIF

Drug updated on 4/18/2024

Dosage Forminjectable (intravenous; 15.5 MBq/mL to 308.2 MBq/mL [0.42 mCi/mL to 8.33 mCi/mL])
Drug ClassRadioactive diagnostic agents
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). Fluorodopa F 18 PET is an adjunct to other diagnostic evaluations.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Fluorodopa F 18 is indicated for use in positron emission tomography to visualize dopaminergic nerve terminals in the striatum for evaluating adult patients with suspected Parkinsonian syndromes, serving as an adjunct to other diagnostic evaluations.
  • Four systematic reviews/meta-analyses compared Fluorodopa F 18's safety and effectiveness with other diagnostic methods or radiopharmaceuticals within specific population subgroups.
  • In young patients presenting with parkinsonian symptoms such as Dopamine Responsive Dystonia (DRD) and Juvenile Parkinsonism (JP), Fluorodopa F 18 PET scans provide a viable alternative when genetic testing is not feasible due to accessibility or cost issues. This radiopharmaceutical shows distinctive patterns of decreased uptake in JP cases, while DRD results are comparable to those in normal subjects.
  • For brain tumor evaluation, particularly gliomas, Fluorodopa F 18 PET has shown superior effectiveness over traditional fluorine-18 fluorodeoxyglucose PET/CT due to its metabolic imaging capabilities with amino-acid radiotracers like itself.
  • Studies found that the detection rate using Fluorodopa F 18 for recurrent Medullary Thyroid Carcinoma (MTC) was significantly higher than other modalities, regardless of serum calcitonin or CEA levels and calcitonin doubling time, suggesting broader applicability across patient subgroups.
  • Lastly, among various PET tracers used for detecting brain tumors including 11 C-methionine, 11 C-choline, etc., radiolabelled amino acid tracers like Fluorodopa F 18 showed the highest diagnostic performance, indicating its superiority over others, especially in terms of prognostic value for glioma patients.